Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Debt / NOTE 1.250% 9/1
-
Number of holders
-
64
-
Total 13F principal, excl. options
-
1,003,179,309
-
Principal change
-
+1,003,179,309
-
Total reported value, excl. options
-
$1,128,882,513
-
Value change
-
+$1,128,882,326
-
Number of buys
-
65
-
Price
-
$1.12
Significant Holders of SAREPTA THERAPEUTICS INC - NOTE 1.250% 9/1 as of Q3 2023
65 filings reported holding 803607AD2 - SAREPTA THERAPEUTICS INC - NOTE 1.250% 9/1 as of Q3 2023.
SAREPTA THERAPEUTICS INC - NOTE 1.250% 9/1 has 64 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $1,003,179,309 of principal
.
Largest 10 bondholders include Linden Advisors LP ($154,150,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($74,975,000 of principal), Calamos Advisors LLC ($59,575,000 of principal), Opti Capital Management, LP ($49,000,000 of principal), LAZARD ASSET MANAGEMENT LLC ($48,344,000 of principal), BANK OF AMERICA CORP /DE/ ($44,500,000 of principal), BRAIDWELL LP ($44,166,000 of principal), Davidson Kempner Capital Management LP ($42,000,000 of principal), Voya Investment Management LLC ($41,945,000 of principal), and ADVENT CAPITAL MANAGEMENT /DE/ ($41,435,000 of principal).
This table shows the top 64 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.